mHealth Israel

Feb 22: BrainHealth at the Crossroads- Investment & Go-To-Market

Sun, Feb 22 · 9:00 AM IST

Herzog Law, 6 Yitzhak Sade, 2nd Floor, Tel Aviv, IL

Funding for Israeli Mental Health startups grew 150% last year, and the number of companies increased by 50% ('source: StartupNation Central). That surge in a reaction to October 7th. But what comes next? The sector is at a crossroads. The focus is now monetization, partnerships and go-to-market. On Sunday, February 22nd, join thought leaders, including from the US, providing insights about mental healthtech go-to-market, partnerships and investment. Register HERE

Agenda:
- Israel 2026 Mental Health Landscape (Gila Tolub)
- US Go-To-Market (Esther Howard)
- MAFAT / IDF Perspective (Alona Barnea)
- Investors Perspective (VC panel: Lena Rogovin, Josh Schulman)
- Moderator: Goel Jasper, FINN Israel
Venue: Herzog law firm, 6 Sadeh Street, Tel Aviv
Time: 9am doors open; 9:30-11:30 content

Step away from the desk and engage with investors and global thought-leaders. Join "BrainHealth at the Crossroads", Feb 22nd, 9-11:30am in Tel Aviv.

Tokyo Growth Machine© March 23-26

Mon, Mar 23 · 2:00 AM IST

Sheraton Miyako Hotel, 1-1-50, Shirokanedai, Minato-ku, Tokyo 108-8640, Japan, Tokyo, JP

Tokyo Growth Machine©**, Powered by mHealth Israel**

Interview and approval required. This is for Series A / B (and beyond) biotech and medical device companies that have raised at least $10m with traction in either the US or Israel. Time in Tokyo is dedicated to meetings with Japanese corporates and investors. To arrange an interview, contact horigome.mihoko.0318@gmail.com

Application Deadline: Feb 10th
Eligibility: Series A / B Israeli biotech and medical device companies, with at least $10m raised in equity / grants
Online Program (Feb 24-March 17):
- Pre-visit: 4 online sessions focused on Japan Healthcare market
Online Sessions:
• Market Overview
• NHI Pricing & Reimbursement
• Regulatory Pathways & Market Access
• Provider Landscape & Care Delivery Models
• Pharmaceutical Market Dynamics
• MedTech & Diagnostics Market Overview
• Long‑Term Care & Elderly Care Market
• Commercial Strategy & Go‑to‑Market Models
• Competitive Landscape & Case Studies
• Working with Japanese Corporates
• Negotiation in a Japanese context

Tokyo Schedule (March 23-26):
- 20 Japanese corporates (half pharma, half medical device)
- 15 Japan-based healthtech investors
- 3 relevant government agencies
Accommodations (paid by attendees): 5 star Sheraton / Miyako. JPY 23,000 (double occupancy); JPY 21,000 (single occupancy

Background: Systematic program for ultra-high potential, market-ready, Series A / B Israeli founded biotech and medical device companies.

Why: Japan is the world #4 healthcare market. Unfortunately, Israel ranks #40 among countries exporting to Japan. The Tokyo Growth Machine© combines systematic preparation with a robust network of relationships and track record securing local partnerships.

Mentors: 20 Tokyo-based mentors spanning regulatory, finance, technology, investment and other key sectors. This group can provide valuable insights and introductions.

Past Results: This team has an unrivaled track record of bridging Israel / Japan and securing corporate partnerships on behalf of Israeli HealthTech companies.

Principal Partners, Japan:

• METI, the Japan Ministry of Economy, Trade and Industry
• FujiFilm (world leader in imaging and medical devices)
• Astellas (#2 Japanese pharma)
• Many, many other Japanese companies committed to participate

Participation Fee: $2500, excluding flight, hotel and travel expenses. Companies may also pay via equity options, but at higher exchange.

Team:
Gali Einav, PhD
• Co-Founder, Vetted VC Accelerator; General Partner, Vetted VC
• Program Head, Adelson School of Entrepreneurship, Reichman University
• Professor of Entrepreneurship, Yeshiva University
• Director, Digital Research, NBC ]Universal
• Advisory Board: Nielsen Innovate Fund; Yeshiva Univ. Innovation Lab
• MA, Hebrew University; PhD, Columbia University

Levi Shapiro
• Founder and Chair, mHealth Israel (12,000+ Israeli tech ]entrepreneurs)
• Board Member: 4 startups
• Veritas Ventures, Gemini Israel Partners
• Founder, 3 startups
• MNC Experience: IBM (Europe), Toyota (Japan)
• Tulane, Cornell, MIT (MBA)

Oren Kaplan
• Meitav (Israel’s largest investment house by AUM), Member of the Board and Founder, Meitav Global Markets
• Co-Founder / CEO, Sharing Alpha (Trip Advisor for Limited Partner investors; Acquired)
• Textbook author, “Behavioral Finance”
• Dealroom manager, Bank Otsar Hahayal and Bank Hapoalim
• UCL (Economics), Tel Aviv University / Wharton (MBA)

Amir Melnikov
• Head of R&D, International Program Manager, Directorate of Defense Research & Development
• Executive Officer, MEIMAD (110m NIS venture capital fund)
• R&D and Engineering Team Leader, Israel Defense Force
• Researcher, Superconductivity and Magnetic Measurements Institute, Bar Ilan University
• Bar Ilan (Physics), Reichman (MBA), Tokyo Institute of Technology (MA, Engineering)

Mihoko Horigome (MS, MBA)
• Senior Sales Executive, Bioscience Division, Thermo Fisher, Japan
• Masters of Biology / Neuroscience, Nagoya University
• MedTech MBA, Hebrew University

To Apply: Contact Levi.Shapiro@gmail.com; +972.52.3424.149 to schedule a Zoom discussion.

March 29: PharmaTech Future Forward

Sun, Mar 29 · 4:00 PM IDT

Naschitz Brandes Amir, Tuval 5,, Tel Aviv, IL

PharmaTech is transforming how drugs are discovered, developed, regulated, and delivered. It’s the engine turning breakthrough science into scalable, data-driven innovation for patients. On March 29th, join thought leaders and budget owners spanning Big Pharma, Venture Capital and others at "PharmaTech Future Forward", 4-6pm, Naschitz Brandes & Amir law firm, 5 Tuval Street, Tel Aviv. Details Below:

Registration via LUMA: https://luma.com/zsvd6fuw
Date: Sunday, March 29th
Time: 4-6pm
Agenda:
MNC Perspective: Lena Granovsky, Head of Israel R&D site / Senior Director, AI / ML, GSK Pharma
Investors Roundtable: Gal Noyman Veksler, PhD, Partner, LionBird (US based); More to come.
Pharma in Japan; Mihoko Horigome, mHealth Israel
Moderator: Goel Jasper, FINN Partners

Join the leaders shaping convergence and help define PharmaTech’s next chapter. Sunday, March 29th, 5 Tuval Street, Tel Aviv. Link for registration is HERE; https://luma.com/zsvd6fuw

EU MedTech Regulatory & GTM

Wed, Apr 15 · 9:00 AM IDT

Herzog law, 6 Yitzhak Sadeh, 1st Floor, Tel Aviv, IL

Three experts, coming from Glasgow, Stockholm and London: Europe MedTech Regulatory & Go-To-Market Workshop, with Edward Staunton, Fredrik Johansson and Mel Wallace..

Cut through the noise of EU MDR, IVDR, and market access challenges. Experts with decades of experience share their practical regulatory and GTM best practices. Venue is Herzog Towers, 6 Sadeh, TLV.

Key Sections:
• Breakdown of the EU regulatory landscape, including compliance
• Guidance on classification, documentation, timelines and BUDGET
• Hospital pilot structures that prove cost savings in real workflows
• Economic cases tailored to payer and hospital incentives

This hands-on workshop will help you avoid regulatory and Go-To-Market hurdles and make Europe a launchpad, instead of a bottleneck.

Title: Europe MedTech Regulatory & GTM Workshop, with Edward Staunton, Fredrik Johansson and Mel Wallace
Speakers: Edward Staunton, Director, Regulatory Affairs & Quality, Clinigen.
Fredrik Johansson, Director, Business Development, Commercial Strategy, Clinigen
Mel Wallace, Vice President, Clinical Supplies Management, Clinigen
Time: 9-11am (9:30 start)
Venue: Herzog Towers, 6 Sadeh, Tel Aviv
MC: Goel Jasper, FINN Partners
Agenda:
9:00-9:30 Registration and networking
9:30-9:35 Welcome Remarks, Goel Jasper
9:35-9:40 mHealth Israel Introductory Remarks
9:40-9:50 Introduction to Clinigen, Mel Wallace, VP, Clinical Supplies Management
9:50-10:25 EU MedTech Regulatory Workshop, led by Edward Staunton
10:25-10:50 EU MedTech Go-to-Market insights, Frederik Johanssen

See you at Herzog Towers, 6 Sadeh, TLV, for Europe MedTech Regulatory & GTM Workshop, with Edward Staunton, Fredrik Johansson and Mel Wallace.